SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones - Seite 2
Erez Nachtomy, CEO of SHL, remarked: "The results from 2023 reflect our strategic approach towards stable growth and financial stability amidst the dynamic market landscape. Our achievements in Israel, the advancement of our Virtual Visit services in Germany, and our focused investments in the US market provide the fundament for further growth. Our commitment remains steadfast on driving growth, enhancing financial stability, and meeting our strategic milestones, all while delivering value to our customers and stakeholders and leading the charge in the telemedicine landscape."
Conference Call 4 pm CET / 10 am ET / 5 pm Israel Time
The conference call can be accessed live via the below dial-in numbers:
From Europe |
+41 (0)58 310 50 00 |
|
From the UK |
+44 (0) 207 107 06 13 |
|
From the USA |
+1 (1) 631 570 56 13 |
|
From Israel |
+972 3763 1173 |
|
Toll free: |
1 80 921 44 27 |
|
Local: |
+972 3763 1173 |
Other international numbers are available here.
After the presentation, there will be an open Q&A. The conference call is scheduled to last 40-60 minutes and will be held in English.
The presentation is available on: www.shl-telemedicine.com/reports
The Full-Year Report 2023 is available on: www.shl-telemedicine.com/reports
SEC submission of the Full-Year Report and presentation is available on:
https://www.shl-telemedicine.com/sec-filing/
Lesen Sie auch
About SHL Telemedicine
SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on
cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and
Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP:
78423T200). For more information, please visit our website at www.shl-telemedicine.com.